EGFR and non-small cell lung carcinoma: NGS allows to identify co-occurring genetic alterations in a specific subgroup of molecularly classified patients and better define the genomic complexity and the prognosis of patients with cancer, as in the case of KRAS mutant [6] or EGFR mutant NSCLC tumors [7,8].